£2.7m Trial: Can a Jab Fight Liver Disease?

A significant £2.7 million clinical trial is set to explore the potential of a weight-loss jab in treating patients with both alcohol dependency and obesity. NHS data indicates these are leading causes of liver disease. This four-year study will focus on semaglutide, also known by the brand name Wegovy.

Research teams based in Nottingham and Plymouth will lead the initiative. From next month, they plan to enroll around 270 NHS patients from the UK who are affected by both alcohol misuse and obesity. The objective is to pioneer new therapeutic strategies for alcohol-related liver disease and obesity, addressing a critical public health challenge.

Alcohol misuse represents a primary cause of preventable mortality, imposing an estimated annual cost of £5 billion on the NHS. This trial aims to provide a much-needed intervention for a complex health issue.